---
title: "12 Health Care Stocks Moving In Monday's After-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304909881.md"
description: "During Monday's after-market session, several healthcare stocks experienced significant price movements. Gainers included Karyopharm Therapeutics (+10.0%), Fractyl Health (+5.89%), and Ovid Therapeutics (+5.26%). Conversely, losers featured Tvardi Therapeutics (-8.5%), Acadia Pharmaceuticals (-7.28%), and Estrella Immunopharma (-5.24%). These shifts occurred following recent earnings reports for some companies."
datetime: "2026-11-09T21:05:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304909881.md)
  - [en](https://longbridge.com/en/news/304909881.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304909881.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Monday's After-Market Session

### Gainers

-   **Karyopharm Therapeutics** (NASDAQ:KPTI) stock moved upwards by 10.0% to $0.04 during Monday's after-market session. The company's market cap stands at $1.2 million.
-   **Fractyl Health** (NASDAQ:GUTS) stock moved upwards by 5.89% to $0.95. The company's market cap stands at $12.3 million.
-   **Ovid Therapeutics** (NASDAQ:OVID) stock moved upwards by 5.26% to $3.0. The company's market cap stands at $556.5 million.
-   **ARS Pharmaceuticals** (NASDAQ:SPRY) stock increased by 3.17% to $3.25. The market value of their outstanding shares is at $280.4 million. As per the press release, Q3 earnings came out 2 days ago.
-   **Altimmune** (NASDAQ:ALT) shares moved upwards by 2.99% to $2.18. The company's market cap stands at $404.5 million.
-   **CEL-SCI** (AMEX:CVM) shares rose 2.96% to $1.39. The company's market cap stands at $25.5 million.

### Losers

-   **Tvardi Therapeutics** (NASDAQ:TVRD) shares declined by 8.5% to $1.29 during Monday's after-market session. The company's market cap stands at $12.7 million.
-   **Acadia Pharmaceuticals** (NASDAQ:ACAD) shares decreased by 7.28% to $15.3. The market value of their outstanding shares is at $3.6 billion. The company's, Q3 earnings came out 3 days ago.
-   **Estrella Immunopharma** (NASDAQ:ESLA) stock fell 5.24% to $0.49. The company's market cap stands at $16.3 million.
-   **Obsidian Therapeutics** (NASDAQ:OBX) shares decreased by 5.18% to $13.0. The market value of their outstanding shares is at $856.4 million.
-   **ALX Oncology Holdings** (NASDAQ:ALXO) stock fell 5.06% to $1.22. The market value of their outstanding shares is at $155.4 million.
-   **Optimi Health** (NASDAQ:OPTH) stock decreased by 4.63% to $2.38. The market value of their outstanding shares is at $13.3 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [ACAD.US](https://longbridge.com/en/quote/ACAD.US.md)
- [CARA.US](https://longbridge.com/en/quote/CARA.US.md)
- [ESLA.US](https://longbridge.com/en/quote/ESLA.US.md)
- [GUTS.US](https://longbridge.com/en/quote/GUTS.US.md)
- [KPTI.US](https://longbridge.com/en/quote/KPTI.US.md)
- [OVID.US](https://longbridge.com/en/quote/OVID.US.md)
- [TVRD.US](https://longbridge.com/en/quote/TVRD.US.md)
- [KPTIQ.US](https://longbridge.com/en/quote/KPTIQ.US.md)
- [ALT.US](https://longbridge.com/en/quote/ALT.US.md)
- [ALXO.US](https://longbridge.com/en/quote/ALXO.US.md)
- [CVM.US](https://longbridge.com/en/quote/CVM.US.md)
- [OBX.US](https://longbridge.com/en/quote/OBX.US.md)
- [OPTH.US](https://longbridge.com/en/quote/OPTH.US.md)
- [SPRY.US](https://longbridge.com/en/quote/SPRY.US.md)

## Related News & Research

- [Ovid Therapeutics Plans Participation in Three Investor Conferences](https://longbridge.com/en/news/304460578.md)
- [Social Media and AI Risks: Compliance, Reputation, and IP Challenges for Ovid Therapeutics](https://longbridge.com/en/news/305118697.md)
- [Ovid Therapeutics Q3 net loss widens as R&D spending rises](https://longbridge.com/en/news/305008804.md)
- [Ovid Therapeutics presents OV329 epilepsy program, targets Phase 2 data in second half of 2027](https://longbridge.com/en/news/305010401.md)
- [Acadia Pharmaceuticals Inc. Just Recorded A 58% EPS Beat: Here's What Analysts Are Forecasting Next](https://longbridge.com/en/news/304760945.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**